Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.
Clinical Stage Pharma
Developing small molecules for the treatment of gastric acid related diseases.
Cinclus Pharma
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.
Our lead asset
Linaprazan glurate
Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.
Latest News
Watch the presentation from Redeye Investor Forum October 10th
Here, you can watch the full presentation (in Swedish) by CEO of Cinclus Pharma, Christer Ahlberg, from Redeye AB Investor Forum October 10th, on the company and the development of linaprazan glurate.
Cinclus Pharma at Redeye Investor Forum in Gothenburg
Cinclus Pharma participates at Redeye Investor Forum in Gothenburg October 10th. Christer Ahlberg, CEO of Cinclus Pharma, will present the company and the development of linaprazan glurate.
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective P-CAB linaprazan glurate and making it available worldwide."
CHRISTER AHLBERG
CEO CINCLUS PHARMA